Decoding Genetics, Ancestry, and Geospatial Context for Precision Health

- 2 Satoshi Koyama M.D., Ph.D.^{1,2,3}, Ying Wang M.D., Ph.D.^{1,4,5}, Kaavya Paruchuri M.D.^{1,2,3}, Md Mesbah Uddin
- 3 Ph.D.^{1,2}, So Mi J. Cho Ph.D.^{1,2,6}, Sarah M. Urbut M.D., Ph.D.^{1,2}, Sara Haidermota B.S.^{1,2}, Whitney E.
- 4 Hornsby Ph.D.^{1,2}, Robert C. Green M.D., M.P.H.^{3,7,8}, Mark J. Daly Ph.D.^{4,5,9,10}, Benjamin M. Neale Ph.D.^{1,4,5},
- 5 Patrick T. Ellinor M.D., Ph.D.^{1,2,3}, Jordan W. Smoller M.D., Sc.D.^{3,11,12}, Matthew S. Lebo Ph.D.^{3,13,14},
- 6 Elizabeth W. Karlson M.D., M.S.^{3,13,15}, Alicia R. Martin Ph.D.^{1,4,5,*}, and Pradeep Natarajan M.D., M.M.Sc^{1,2,3,*}
- 7 1. Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- 8 2. Cardiovascular Research Center and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- 9 3. Department of Medicine, Harvard Medical School, Boston, MA, USA
- 10 4. Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
- 11 5. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Integrative Research Center for Cerebrovascular and Cardiovascular Diseases, Yonsei University College of Medicine,
 Seoul, Republic of Korea
- 14 7. Department of Medicine (Genetics), MassGeneralBrigham, Boston, MA, USA
- 15 8. Broad Institute and Ariadne Labs, Boston, MA, USA
- 16 9. Institute for Molecular Medicine Finland (FIMM), Finland
- 17 10. University of Helsinki, Helsinki, Finland
- Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- 20 12. Center for Precision Psychiatry, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
- 21 13. Mass General Brigham Personalized Medicine, Cambridge, MA, USA
- 22 14. Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
- Division of Rheumatology, Inflammation and Immunity, Department of Medicine, Brigham and Women's Hospital.,
 Boston, MA, USA
- ²⁵ * A.R.M. and P.N. jointly supervised this work.
- 26 Please address correspondence to:
- 27 Alicia R. Martin, Ph.D.
- 28 185 Cambridge Street
- 29 Boston, MA 02114
- 30 <u>armartin@broadinstitute.org</u>
- 31 Pradeep Natarajan, M.D., M.M.Sc
- 32 185 Cambridge Street
- 33 Boston, MA 02114
- 34 pnatarajan@mgh.harvard.edu
- 35 Figures 5
- 36 Supplemental Figures 10
- 37 Supplemental Tables 7
- 38 Supplemental Information (9 Figures)

39 Abstract

- 40 Mass General Brigham, an integrated healthcare system based in the Greater Boston area of
- 41 Massachusetts, annually serves 1.5 million patients. We established the Mass General Brigham
- 42 Biobank (MGBB), encompassing 142,238 participants, to unravel the intricate relationships among
- 43 genomic profiles, environmental context, and disease manifestations within clinical practice. In this
- 44 study, we highlight the impact of ancestral diversity in the MGBB by employing population genetics,
- 45 geospatial assessment, and association analyses of rare and common genetic variants. The population
- 46 structures captured by the genetics mirror the sequential immigration to the Greater Boston area
- 47 throughout American history, highlighting communities tied to shared genetic and environmental factors.
- 48 Our investigation underscores the potency of unbiased, large-scale analyses in a healthcare-affiliated
- 49 biobank, elucidating the dynamic interplay across genetics, immigration, structural geospatial factors,
- 50 and health outcomes in one of the earliest American sites of European colonization.

51 Introduction

52 Determinants of health include a complex interplay of sociodemographic, structural, genetic, and 53 environmental factors that are also contextually dependent on time and geography. Disease risk 54 prediction models and therapeutic paradigms are largely agnostic to many of these important features 55 vet are intended for broad use. Such training datasets often lack the breadth and depth of information 56 and the inherent diversity across features required for equitable applications. The United States 57 populace is highly diverse, marked by complex migration patterns and dynamic social constructs and 58 represents multilevel health contributors. For example, it is widely recognized that the prevalence of 59 diseases is closely linked to individual or neighborhood social deprivation, which further varies across smaller domains and regions^{1,2}. Furthermore, these determinants differentially contribute to health 60 outcomes depending on local factors^{3,4}. 61

62 Contemporary healthcare-associated biobanks represent a new opportunity to discover novel 63 determinants of health and augment translation to clinical care. Such endeavors represent a recent collaborative synergy of large-scale population-based-⁵⁻⁸ and local healthcare- biobanks⁹⁻¹³. 64 Understanding how DNA sequence variation tracks contemporary and historical population 65 demographics can provide insights on differential disease burdens. For example, rs5742904 66 67 (c.10580G>A, p.Arg3527GIn) in APOB, a founder pathogenic mutation for familial hypercholesterolemia has significantly higher allele frequency in Old Order Amish people. It substantially explains the 68 increased risk for coronary artery atherosclerosis in this population^{14,15}. Important insights related to 69 70 genetic variations and clinical outcomes may often require profiling diverse populations. For example, the discovery of the association between disruptive variants in *PCSK9*^{16,17} and lower low-density 71 72 lipoprotein cholesterol in the African population, where these variants are prevalent, facilitated drug 73 development. As another instance, G6PD deficiency¹⁸ was recognized as a prevalent hemolytic 74 disease in Sub-Saharan Africa. Studying diverse populations across a spectrum of diseases is crucial to assess the penetrance of disease-associated monogenic alleles¹⁹ and polygenic models²⁰. 75

76 Recent analyses of biobanks in the United States have uncovered the complex genetic structure of Hispanic and/or Latinx groups tracing their origins to the Americas^{9,12}. In these efforts, it has been 77 78 demonstrated that the fine genetic structure within biobanks can identify varying disease risks by 79 capturing both ancestral and social structures, thereby contributing to the advancement of personalized 80 medicine. Separately, recent advances in data size and methodology have enabled us to precisely characterize the complex population dynamics associated with multiple colonization and admixture 81 82 events²¹⁻²³ However, the interplay across these features, or their interaction with large-scale genetic 83 association studies using whole-genome imputed or sequenced data, remains understudied.

3

- 84 The New England region represents among the earliest European colonization of the United States with
- 85 sequential ongoing migration from diverse groups. In this study, we examined the genetic variation
- 86 across New England coupled with sociodemographic, clinical, and environmental/geospatial factors in
- 87 the Mass General Brigham Biobank (MGBB). By applying a network-based clustering algorithm with
- 88 newly generated reference dataset, we established fine genetic clusters with subcontinental resolution
- 89 within MGBB. These clusters exhibited distinct genetic properties, geographic distributions,
- 90 socioeconomic statuses, and disease risks. In combination with rare and common variant genetic
- 91 association analyses, we gained further insights into the different disease risks among these
- 92 populations. Collectively, this study highlights the power of large-scale, unbiased analyses within a
- 93 healthcare-based biobank to understand the complex interplay between genotypes and phenotypes,
- 94 paving the way for increasingly personalized interventions.

95 Results

96 Participant recruitment and Electronic Health Record (EHR) based phenotyping

- 97 Since 2010, 142,238 individuals within the Mass General Brigham (MGB) network, the largest
- 98 healthcare system in Massachusetts, have consented to participate in the MGBB as of May 11, 2023
- 99 (Figure 1a, Supplemental Information Figure 1, Supplemental Table 1). Among participants, 99.5% (n =
- 100 141,519) consented to re-contact. 56.8% of participants are female (n = 80,851, Figure 1b). Median
- 101 [interquartile range; IQR] age at consent was 51 [35 63] years for female participants and 58 [43 68]
- 102 years for males. Self-reported races were 84.4% White, 4.5% Black, and 3.0% Asian. Self-reported
- 103 ethnicities were 86.6% non-Hispanic and 2.44% Hispanic (Supplemental Information Figure 2). The
- 104 participants are primarily cared for at the two flagship MGB hospitals, both located in Boston, MA, and
- 105 their associated clinics Massachusetts General Hospital (MGH) and Brigham and Women's Hospital
- 106 (BWH, Figure 1c). The biobank data is interlinked with EHRs with phenotype data across the MGB
- 107 network, as well as notable specialty centers in Boston, MA including the Mass Eye and Ear Institute
- 108 (MEEI) and Dana-Farber Cancer Institute (DFCI). To generate systemically annotated
- 109 prevalent/incident outcomes, we extracted International Classification of Diseases codes, Nineth (ICD9)
- and Tenth (ICD10) revisions, from the EHR and mapped them to PheCodes²⁴. We identified 1,577 of
- 111 1,860 possible PheCodes with at least one event (Figure 1d). Participants were followed for a median
- 112 [IQR] of 4.3 [2.5 6.0] years after inclusion to MGBB with a median of 12 [5 25] incident events per
- 113 person.

114 **Fine-scale clustering of genetic ancestry in MGBB**

115 Extending beyond traditional low-dimensional projections of continental ancestry from genome-wide 116 data, we utilized high-dimensional principal components (PCs) to achieve greater granularity. Using 117 genome-wide genotyping arrays, we genotyped 53,306 participants in the MGBB. By employing the top 30 genetic PCs and a network-based clustering approach²⁵, we identified 30 data-driven distinct 118 119 ancestral clusters (Figure 2a, 2b, and 2c, Figure S1, Supplemental Table 2). The largest cluster (cluster 120 0, ordered by sample size) includes 11,875 (22.3%) MGBB individuals. The smallest (cluster 29) 121 includes only one MGBB participant as well as 27/27 reference Sardinian individuals from Human 122 Genome Diversity Project (HGDP)²⁶, suggesting the origin of this individual. As such, unsupervised

- 123 clustering with diverse populations from the 1000 Genomes Project Phase 3 (1KG)²⁷ and HGDP
- 124 reference panels²⁸ allowed us to infer the genetic similarity between these clusters and populations
- 125 worldwide in an unbiased manner.

126 Cluster 0 was genetically similar to the Western European populations in the reference dataset (CEU

127 [Utah residents with Western or Northern European ancestry] and GBR [British from England or

128 Scotland] in 1KG, French and Orcadian in HGDP, Figure S2). In addition to the cluster 0, we identified

129 eight distinct 1KG+HGDP-EUR-like clusters that cluster with Italian, Russian, Spanish, Adygei, Finnish,

130 Basque, and Sardinian ancestries reflecting known patterns of migration to the Greater Boston Area.

131 We also identified two distinct 1KG+HGDP-AMR-like clusters (cluster 5 enriched with PUR [Puerto

132 Rican in Puerto Rica], cluster 8 with Colombian, Maya, PEL [Peruvian in Lima, Peru], Pima, CLM

133 [Colombian in Medellín, Colombia], MXL [Mexican ancestry in Los Angeles, CA]), four African-like

134 clusters (cluster 6 enriched with African Caribbean in Barbados and African Ancestry in Southwest USA,

135 cluster 17 specific to Nigerian Africans [Esan in Nigeria, Yoruba in Ibadan, Nigeria], cluster 22 specific

136 to Kenyan Africans [Bantu and Luhya in Webuye, Kenya], and cluster 18 with other Western Africans

137 [Mandinka, Mende people in Sierra Leone, Gambian in Western Divisions in the Gambia]), and three
 138 East Asian-like clusters (cluster 19 specific to Japanese, cluster 20 specific to Uygur, and cluster 9 with

139 other East Asians). We identified a single large cluster (cluster 10) enriched in South Asian reference

140 populations, however, Hazara and Kalash populations formed distinct clusters.

141 Even with a diverse reference dataset, eight clusters comprising 9,874 (18.8%) MGBB individuals did

142 not have enrichments of specific populations from the reference dataset. Among these unannotated

143 clusters, seven clusters (4,7,11,13,14,15, and 21) exhibited genetic similarities to 1KG+HGDP-EUR

144 populations. We calculated pairwise Fixation Index (F_{ST}) values among clusters, and then constructed a

145 phylogenetic tree of the clusters. The observed population differentiation between clusters further

146 corroborates the ancestral relationships but notable distinctions from continental populations and147 residents in New England (Figure S3a).

We also conducted ADMIXTURE²⁹ analyses to infer continuous population structures within these 148 genetic clusters, many of which show similar patterns of structure across increasing numbers of 149 150 ancestral components (Figure S3b). Using cross validation, ten was the best fit number of components 151 (Supplemental Information Figure 3). We identified two 1KG+HGDP-EUR-like components 152 (distinguished by components 4 and 9). The component 4 was most enriched in the Finnish-like cluster 153 (cluster 24), and relatively enriched in northern European-like clusters (0, 1, and 3) more than the 154 southern European-like clusters (2, 12, and 14). In contrast, the component 9 was enriched in the 155 southern European-like cluster. We also observed a third component included in the European 156 ancestries (component 3). This component 3 is prominent in the Kalash (Indo-European in northwest 157 Pakistan) and other Pakistani reference populations. While this was enriched in southern European-like 158 clusters, it was more enriched in un-annotated European-like genetic clusters 4, 7, 11, 13, and 21 than 159 other annotated European genetic clusters, possibly consistent with Middle Eastern origins as this 160 group is poorly represented in reference datasets.

161 Cluster 4 – the 5th largest cluster in this study (n = 3,514) – is one of such un-annotated European

162 clusters. By comparison of allele frequencies between gnomAD³⁰ ancestries and our dataset, we found

163 that cluster 4 has allele frequencies most similar to the Ashkenazi Jewish reference population

164 (Supplemental Table 3). We also observed strong enrichment of skin neoplasms and inflammatory

165 bowel diseases which were previously noted to be enriched in known Ashkenazi cohorts (Figure S4).

166 We also observed significant enrichment of Ashkenazi Jewish founder mutations (e.g., APC c.3920T>A,

167 p.lle1307Lys, *BRCA1* c.68_69del, p.Glu23fs, *BRCA1* c.5266dup, p.Gln1756fs, *BRCA2* c.5946del,

168 p.Ser1982fs)^{31,32} in this genetic cluster (Figure S5). We also observed enrichments of these founder

169 mutations in un-annotated European clusters 11 and 14 suggesting close genetic relationships between

170 these clusters to the Ashkenazi-like cluster 4. In addition to the European-like components, we also

171 identified two different components (components 5 and 7) enriched in the East Asian clusters. One of

these components (component 5) was also observed in the Finnish-like cluster which is consistent with

173 previous observations³³⁻³⁶.

7

174 Effective population size of ancestry clusters in the Greater Boston area

175 To characterize the ancestral clusters observed in the MGBB, we estimated the historical transition of 176 effective population size of each cluster using genome-wide genetic data (Figure S6). We conducted 177 IBD-based estimation for effective population sizes (N_e). Our results were consistent with some prior 178 results conducted outside of the U.S. For example, we replicated previously described bottleneck event 179 in Ashkenazi-like population (cluster 4). The lowest N_e was estimated to be 1,170 (95% CI = 1,100 -1,270) individuals at 28 generations ago³⁷. We observed similar bottleneck events in clusters 11 and 14 180 181 around the same generation (minimal N_e was 4,570 [4,210 – 5,030] in cluster 11 and 32,600 [30,700 – 182 35,900] in cluster 14) consistent with the aforementioned sharing pattern of Ashkenazi founder 183 mutations with cluster 4. The largest genetic cluster 0 indicates a population bottleneck occurring 184 approximately 12 generations ago. This timeframe coincides with the initial colonization of the Boston 185 area by British settlers. Intuitively, this event is not evident in the British population from the UK Biobank. (UKBB) here or in previous studies^{38,39} (Supplemental Information Figure 4), suggesting a unique 186 187 founder event among British Americans due to colonization. We also observed a significant bottleneck 188 event in the Admixed American populations, specifically in clusters 5 and 8, with a pronounced 189 magnitude in the Puerto Rican-like cluster 5 (minimal N_e was 11,300 [11,100 – 11,600]). However, we 190 did not observe such bottlenecks for other clusters potentially reflective of more continuous migration.

191 Genetic clusters, geographic and socioeconomic factors, and disease risks

We used geospatial scan statistics to understand the geographical structure of MGBB ancestry clusters.
 We observed 22 statistically significant regions of geographical enrichment among 13 genetic clusters

- 194 in smaller than 4-km radius areas. We observed distributions of genetically inferred clusters
- recapitulating colonization histories into the Greater Boston Area (Figure 3a). One example of strong
- 196 enrichment was observed in the southern area (Roslindale / Mattapan / Dorchester and separately
- 197 Roxbury) by cluster 6 (ACB [African Caribbean in Barbados] and ASW [African ancestry in Southwest
- U.S.], expected number 105 and observed number 725, $P < 1 \times 10^{-17}$). Another strong enrichment is
- 199 observed northern of Boston (Charlestown / Chelsea) by cluster 5 (PUR [Puerto Rican in Puerto Rico],
- expected number 180 and observed number 624, $P < 1 \times 10^{-17}$) in addition to Boston's South End
- 201 extending to Roxbury / Hyde Park / Jamaica Plain. We also observed enrichment of Ashkenazi Jewish-
- 202 like (cluster 4) and East Asian-like clusters (cluster 9) in areas seeded by early founding communities,
- such as Back Bay / Brookline / Cambridge (cluster 4) and Allston (cluster 9), respectively.

204 The western European-like clusters cluster 0 and cluster 1 were similar in conventional PC space

- 205 (Figure S1) and ADMIXTURE analysis (Figure S3b)²⁹, but well differentiated by network-based
- 206 clustering (Figure 2a) as well as geospatially. The CEU/GBR-like cluster 0 was enriched in central
- 207 areas of the Boston (Beacon Hill) and Cambridge (Harvard Square), representing the earliest sites of
- 208 British colonization. Cluster 1 (Orcadian-like, tagging northern populations of the British Isles including
- those hailing from Scotland and Ireland) is enriched in two different geographical locations, including
- 210 Chelsea and South Boston, where secondary colonization occurred. These different geographical
- 211 enrichments of cluster 0 versus cluster 1 reflect the distinct histories of these two similar, but distinct
- 212 genetic European ancestries.
- 213 Socioeconomic status was correlated with both genetic ancestry as well as ancestral geographic
- distributions¹. Using geocoded location information for each participant in our study, we calculated a
- 215 Social Deprivation Index (SDI, ranged from 0 to 100, higher SDI indicating greater deprivation) for each
- 216 participant and associated this with healthcare outcomes (Figure S8, Supplemental Table 4). The
- 217 distributions of SDI widely differed across genetic ancestries (Figure S7a). Specifically, Cluster 6
- 218 (enriched with African Caribbean in Barbados like population) exhibited the highest level of deprivation,
- 219 with a median [IQR] SDI score of 83 [52 94]. Conversely, Cluster 4 (Ashkenazi Jewish-like) had the
- lowest deprivation, as indicated by a median [IQR] SDI score of 22 [8 45].

To systemically identify the associations between socioeconomic status and disease risk in MGBB, we associated SDI with phenome-wide outcomes captured by EHRs, adjusting for genetic ancestries. We

223 found SDI was significantly associated with 400 out of 1,564 phenome-wide outcomes (Bonferroni P <

- $0.05/1,564 = 3.2 \times 10^{-5}$, Figure 3b). Greater SDI was generally associated with increased disease
- 225 prevalence and incidence (385 out of 400). The strongest SDI-associated PheCodes was with Tobacco
- use disorder (odds ratio; OR [95%CI]) per one standard deviation (SD) of SDI was 1.54 [1.48 1.60],
- 227 followed by Mood disorders (OR = 1.26 [1.23 1.30]), and Depression (OR = 1.26 [1.23 1.30]). As
- represented by these examples, we observed greater risks for Mental disorders, followed by
- 229 Uncharacterized Symptoms, Respiratory, and Circulatory systems per PheCodes categories,
- 230 respectively (Figure 3c). However, prostate (OR 0.85 [0.80 0.90]) and breast (OR 0.89 [0.84 0.95]),
- 231 cancer had significant/nominal negative associations with SDI (Figure 3b).
- Using coronary artery disease (CAD) as an example of a common complex condition, we identified a
- 233 significant association between SDI and CAD independent from clinical and genetic risk. The
- association remained significant even after adjustments for clinical risk score (Pooled Cohort Equation,
- 235 PCE)^{40,41}, and polygenic risk score⁴² (PRS, $OR_{1SD-SDI} = 1.26 [1.17 1.35]$, $OR_{1SD-PCE} = 1.73 [1.65 1.25]$
- 1.81], OR_{1SD-PRS} 1.24 [1.13 1.36], in the multivariate model adjusted by the first ten genetic PCs,
- 237 Figure S7).

238 Exome Sequencing in MGBB

- 239 Using high-coverage whole exome sequencing in the same group of individuals, we systemically
- 240 identified rare coding variants in MGBB. There were significant differences in variant distributions
- across clusters. For instance, the Ashkenazi-like cluster 4 had fewer singleton variants (median [IQR] =
- 138 [126 152] for cluster 4, and 489 [408 566] for others). In contrast, there were significantly more
- singletons in clusters 11 and 14, even though they are closely related to cluster 4 (320 [294 361] and
- 244 400 [372 436], respectively, Supplemental Information Figure 5).
- 245 We identified median 15 [12 18] rare (Minor allele frequency, MAF < 0.01), high-confidence predicted
- loss-of-function (pLOF) variants per participant (Figure 4a). The largest number of pLOF variants were
- 247 observed in African-like clusters (23.5 [20.25 26.0] in cluster 22, 21 [19 22] in cluster 26, 21 [17 –
- 248 24] in cluster 17, 20 [17.0 23.0] in cluster 6). The Northern European-like clusters 1 and 0 had the
- 249 fewest pLOFs (13 [11.0 16.0] in cluster 1 and 14 [12 17] in cluster 0 and 3). We also identified 1,425
- 250 individuals (2.8% of total population) with at least one rare autosomal pLOF homozygous genotype
- across 761 genes.
- We next explored established pathogenic variants (Figure 4b) in MGBB. 2.6% (1,318/50,625) of
- 253 participants carry a potentially actionable pathogenic/likely pathogenic variant per American College of
- 254 Medical Genetics and Genomics secondary findings guideline (ACMG SF, version 3.1)^{43,44}. These
- included 6 homozygotes (TP53, LDLR, 4 MUTYH), and 7 potential compound heterozygotes (2 BTD, 3
- 256 *MUTYH*, *ATP7B*, and *GAA*). Across genetic clusters, we observed substantial differences in the
- 257 prevalence of these pathogenic variants (Figure 4c). The highest rate of actionable findings (> 4%) was
- 258 observed in clusters 11 and 4 despite generally having the lower prevalence of very rare variants.
- 259 Conversely, non-European clusters generally showed lower rates for annotated actionable variants.
- 260 Considering higher number of alternate allele-counts in the non-European clusters, the genetic
- 261 diagnostic rate was significantly lower in non-European populations (Figure S9). Namely, pLOF variants
- 262 on ACMG SF v3.1 genes found in African and East Asian clusters have significantly lower likelihood of
- being annotated with a high-quality (more than equal two-stars) pathogenic/likely pathogenic annotation
- in comparison to the European participants ($OR_{AFR} 0.27 [0.18 0.41]$ and OR_{AMR} and 0.48 [0.35 0.65],
- 265 tested by Fisher's exact test), at least partly related to the underrepresentation of causative variants
- recurrently observed in non-European groups in the ClinVar^{45,46} database.
- 267 To understand the clinical consequences of rare coding variants, we performed exome-wide and
- 268 phenome-wide association study (PheWAS) across 1,454 PheCodes and 14,912 genes. We did not
- 269 find substantial evidence of inflation in the test statistics (median Lambda $GC_{1.0\%}$ 0.89 [0.86–0.93] for
- 270 AFR, and 0.90 [0.87 0.93] for AMR, 1.02 [0.99 1.05] for EUR, Supplemental Information Figure 6a).

- 271 We identified 51 significant associations ($P < 1.8 \times 10^{-9}$, 0.05/28,035,307 tested phenotype-transcript
- pairs, Supplemental Table 5) in the burden of rare pLOF and deleterious missense variants with 14
- 273 genes, which included 8 ACMG SF v3.1 genes across 45 clinical outcomes (Figure 4d). In addition to
- the genes associated with known traits, we found significant associations between *PTEN* deleterious
- variants and increased risk for secondary hypothyroidism. This link was not described by previous rare
- 276 variant targeted analysis^{47,48} while *PTEN* deleterious variants have been known to be causal for
- hamartoma syndrome including thyroid cancers and abnormalities^{49,50}. Nevertheless, we highlight
- 278 numerous persistent risk signals from known Mendelian mechanisms of disease in MGBB.

279 Genome-wide PheWAS in MGBB

280To further explore the relationship between genotype and phenotype in MGBB, we conducted a281comprehensive genome-wide PheWAS using ICD code-based PheCodes. We associated over 20

- million common variants in African, European, and Admixed populations, which were imputed using the
- TOPMed imputation reference panel,⁵¹ with 1,461 PheCodes. Similar to the rare variant burden test, we
- observed calibrated test statistics overall (median Lambda GC [IQR] were 0.98 [0.95 1.00] for AFR,
- 285 0.97 [0.93 1.00] for AMR, 1.02 [0.99 1.03] for EUR, Supplemental Information Figure 6b). We
- identified 111 associations that reached genome-wide significance ($P < 5 \times 10^{-8}/3,048 = 1.6 \times 10^{-11}$,
- Figure 5a, Supplemental Table 6), including 3 African and 1 AMR associations. We refined the
- 288 prognosis of identified known low-frequency monogenic variants. For instance, we observed that the
- variant rs6025 (*F5,* c.1601G>A, p.Arg534GIn; Factor V Leiden) is strongly associated with Congenital
- deficiency of other clotting factors, including factor VII (OR [95%CI] = 11.56 [9.37 14.27], $P = 3.6 \times 10^{-10}$
- 291 10⁻⁶⁸). Similarly, rs113993960 a pathogenic variant in *CFTR* (c.1521_1523del, p.Phe508del) is
- 292 associated with Cystic fibrosis (OR 14.67 [11.66 18.44], $P = 2.4 \times 10^{-87}$).
- 293 Some of these variants exhibited a pronounced recessive effect on the phenotype. A prime example is
- the variant rs72660908, which is associated with Rhesus isoimmunization in pregnancy (Figure 5b).
- 295 This medical condition exemplifies recessive inheritance resulting from the deletion of the *RHD* gene.
- As anticipated, the OR for heterozygotes was not significant ($OR_{Hetero} = 1.18 [0.53 2.7]$) compared to
- the strong effect observed in homozygotes ($OR_{Homo} = 24.3 [14.6 43.1]$, Figure 5c). Recent large-scale
- 298 sequencing analysis of structural variants⁵² identified high linkage disequilibrium (LD) between
- rs72660908 and a large deletion affecting *RHD* ($R^2 > 0.99$), which we support by strong expression
- 300 quantitative trait loci (eQTL) effect of rs72660908 on *RHD*⁵³ (Figure 5d) and low coverage by exome
- 301 sequencing in the MGBB (Supplemental Information Figure 7). We also observed a significant
- enrichment of cases among individuals who were homozygous for rs72660908, with 127 out of 156
 cases having the G/G genotype at this locus. As previously reported, individuals with the homozygous
 alternate allele for rs72660908 have a recessive inheritance pattern in European ancestry populations,
 but the frequency fluctuates among clusters (17% in cluster 0 and 9% in cluster 4, Figure 5e), and we
 observed very few copies in AFR/EAS populations.

Another noteworthy example is the association between rs73404549 and sickle cell anemia in the AFR population. This variant is in strong LD with rs334 (*HBB* c.20A>T, p.Glu7Val, HbS), a well-established pathogenic variant for sickle cell anemia. Despite high medical relevance, rs334 was not included in the TOPMed reference panel. We re-evaluated the impact of rs334 using exome sequencing data on sickle cell anemia and clinical red blood cell counts. rs334 showed stronger and more penetrant effect size for

- 312 sickle cell anemia than imputed rs73404549 ($\beta_{rs334} = 4.14 \pm 0.25$, $P_{rs334} = 5.9 \times 10^{-94}$, $\beta_{rs73404549} = 3.05 \pm 10^{-94}$
- 313 0.22, $P_{rs73404549} = 4.4 \times 10^{-46}$) with 14 homozygotes for rs334 and a penetrance rate of 79% (Figure
- S10a). Additionally, we noted another missense variant rs33930165 in HBB (HBB c.19G>A, p.Glu7Lys,
- HbC) previously shown to confer malarial resistance without sickle cell anemia. We found 5
- 316 participants with sickle cell anemia heterozygous for both HbS or HbC with significantly lower red blood
- 317 cell counts compared to heterozygotes for either genotype (Figure S10b).

318 **Discussion**

319 In this study, we conducted multidimensional investigations into the structure of a modern healthcare-320 based biobank based at one of the earliest sites of durable European colonization. We show how 321 expanded immigrant communities in the U.S. often exhibit genetic similarities to contemporary 322 continental populations and reflect common bottlenecks. However, we also observe distinct 323 bottlenecking effects of early colonization and patterns of admixture, and identify populations not well 324 represented in reference datasets. Using geospatial indices, genetic ancestries, and phenome-wide 325 outcome data, we described the architecture of diseases associated with regional socioeconomic 326 factors such as area-level poverty, education level, single parent households, living in rented housing units or overcrowded housing units, living without a care or unemployment⁵⁴. We further leverage rich 327 328 genotyping and phenotyping to clarify several clinically relevant genetic associations complementing 329 clinical and environmental features. This work advances an overall goal of comprehensively quantifying 330 heterogeneous health determinants that uniquely vary across diverse communities in the U.S.

331 Leveraging population genetics, we delineated the complex ancestral components present within the 332 Boston area. While our findings align well with prior studies on nationwide cohorts^{22,23,38,39}, our research 333 offers further granular insights into the individual-level ancestral histories of the participants, including 334 lifestyle, genetic, and social risk factors associated with the diseases. We used genetic variation to 335 explore the dynamic interplay of migration, expanded colonization sites, and geographic and 336 community variation, aiming to study how social deprivation influences health, independent of the 337 clinical and genetic risk factors. With distinctions from continental level ancestral histories, the complex 338 history of communal- and individual-level factors can be uniquely mapped by healthcare-associated 339 biobanks to uncover novel important drivers of health.

340 Area-defined SDI improved prediction performance when incorporated into existing clinical^{55,56} and genetic risk stratification models^{57,58} for common complex diseases. In this study, by integrating large 341 342 scale EHR data and geographical information, we systemically assessed the impact of SDI on 343 Phenome-wide scale across diverse ancestries and drew several clinical implications. First, our 344 systemic assessment suggests that although SDI is a significant contributor to a wide range of diseases. 345 the impacts of SDI are significantly varied across disease domains. For example, while mental and 346 cardiopulmonary diseases are more prevalent among individuals experiencing social deprivation. 347 cancers and congenital diseases are observed almost equally, irrespective of deprivation status. 348 Furthermore, SDI is differentially vet ubiquitously associated with a wide array of health outcomes 349 across various genetic ancestral groups. Finally, although the effect of SDI persisted across various

15

genetic clusters, the varying magnitude of association suggests an interaction between social
 deprivation and genetic factors as previously suggested^{59,60}.

352 In addition to enabling detailed disease modeling, healthcare biobanks are unique and powerful 353 resources for exploring rare genetic conditions or disease outcomes. First, we identified individuals 354 carrying actionable variants, as defined by a curated database. However, these individuals are 355 predominantly of specific European ancestries, suggesting a bias against non-Europeans in reference datasets, potentially resulting from disparities in clinical genetic testing^{19,61}. Using an unbiased genomic 356 357 scan, our study uncovered several significant associations, which may further refine prognosis within 358 healthcare settings. Furthermore, we confirmed a penetrant association between an upstream variant 359 of the *RHD* gene and Rhesus isoimmunization during pregnancy^{13,62}, while also clarifying varied 360 prevalence across diverse communities. Bringing these findings together, we highlight that healthcare 361 biobanks, compared to general population-based biobanks, are enriched with uncommon outcomes. 362 and associated genetic variations, thereby offering an ideal environment to study clinically pertinent 363 scenarios.

Nevertheless, our study warrants several limitations. First, most of our enrollment occurred in tertiary
 hospitals. While this enabled us to include patients with rare and more severe conditions, the

366 prevalence may not reflect the general population due to inclusion bias as previously described⁶³.

367 Second, MGBB participants are centralized in the greater Boston area of Massachusetts, which reflects

the geographic location of the two main hospitals of the MGB health system. Communal and geospatial

369 characteristics are likely to vary in other New England regions and more broadly across the U.S.

370 Moreover, while our study provides detailed insights into European populations, the resolution for non-

European populations is less robust due to limited sample sizes, reflecting the demography of theincluded region.

In conclusion, by utilizing a population genetics, we discerned specific ancestral clusters within the MGBB. These clusters reflect the colonization histories of the Greater Boston area and exhibit distinct genetic characteristics and disease susceptibilities. Individual-level clinical and lifestyle risk factors in combination with community context, structural factors, and genetic variation advance disease modeling toward precision medicine initiatives.

378 Methods

379 Patient recruitment in MGBB and study protocols

380 MGBB, previously known as Partners Biobank, is an integrated research initiative based in Boston, 381 Massachusetts. It collects biological samples and health data from consenting individuals at 382 Massachusetts General Hospital, Brigham and Women's Hospital, and local healthcare sites within the 383 MGB network⁶⁴. This repository of samples and data supports researchers aiming to decipher disease 384 mechanisms, enhance personalized medicine, and innovate therapeutic solutions. Since July 1st, 2010. 385 the MGBB has enrolled 142,238 participants, and extracted DNA from 88,665 participants' samples 386 (62.3%). All participants provided written/electronic informed consent for broad biological and genetic 387 research. The study protocol to analyze MGBB data was approved by the Mass General Brigham 388 Institutional Review Board under protocol number 2018P001236. The study protocols to analyze UKBB 389 data was approved under protocol number 2021P002228 and performed under UKBB application 390 number 7089.

Genotype quality control and imputation

392 53,306 individuals were genotyped by Illumina Global Screening Array (Illumina, CA) in four batches (13,140 in the 1st batch, 11,649 in the 2nd batch, 5,976 in the 3rd batch, and 22,541 in the 4th batch). 393 Genotypes were called using the Z-call software⁶⁵. After genotype calling, we conducted quality control 394 395 with the following steps. We re-aligned genotyping probes to the GRCh38 reference genome using the 396 blast software⁶⁶ and extracted probes with perfect- unique match. We removed indels and multiallelic 397 sites and removed variants with high missingness (> 2%) and low minor allele counts (\leq 2). After 398 genotype quality control, we estimated continental level ancestry using the 1KG dataset. We extracted 399 common, high-quality SNPs (missingness < 1%, MAF > 1%) across MGBB and the 1KG dataset. After 400 pruning SNPs, we computed SNP weights for genetic principal component using the 1KG dataset. 401 Then, we projected MGBB participants into the same principal component space using 10 PCs. Using 402 genetic PCs in 1KG dataset as a feature matrix, we trained a K-nearest neighbor model for population 403 assignment (AFR, AMR, EAS, EUR, and SAS) to assign population labels to MGBB participants. With 404 these inferred labels, we calculated Hardy Weinberg disequilibrium for each population and removed 405 variants with $P < 1 \times 10^{-6}$. Finally, we compared the allele frequency in these populations with gnomAD 406 allele frequency, then removed variants with deviation from ancestry specific gnomAD allele frequency 407 (Chi-square value > 300). These quality control procedures were done by genotyping batch. We took 408 the intersection of the variants in these four batches and generated dataset for imputation. Using the 409 same set of variants, we imputed the genotypes by TOPMed imputation server⁶⁷. We used TOPMed 410 multi-ancestry imputation reference panel (TOPMed r2 panel) including 97.256 reference samples and

17

308,107,085 variants. Pre-phasing was carried out by Eagle software⁶⁸, and imputation was conducted
 by Minimac4 software^{67,69}. After the imputation, we merged all the four batches by vcftools⁷⁰ and

413 converted to bgen file by PLINK2 software (9 Jan 2023)⁷¹ for the downstream analysis.

414 **Exome sequencing and quality control**

Exome sequences were performed by on Illumina NovaSeq instruments (Illumina, CA) with a custom exome capture kit (Human Core Exome, Twist Bioscience, CA), with a target of at least 20x coverage at > 85% of target sites. Alignment, processing, and joint calling of variants were performed using the Genome Analysis ToolKit (GATK, version v4.1)⁷² following GATK best practices. The joint called

- 419 dataset containing all 53,420 individuals processed by Hail framework⁷³ for further 1) genotype, 2)
- 420 variant, and 3) sample quality controls. First, we split the multi-allelic site into biallelic by split_multi_hts
- 421 function. Following this process, we removed low-quality genotypes and genotypes called by
- 422 unbalanced allele balance. We consider genotypes that meet the following criteria as missing: For
- 423 reference homozygotes: total depth (DP) < 10, or Genotype Quality (GQ) < 20. For heterozygotes: DP
- 424 < 10, Genotype Likelihood for reference homozygote (PL) < 20, (Reference depth + A1 depth)/DP < 0.8,
- 425 or (A1 depth)/DP < 0.2. For alternate homozygotes: DP < 10, PL < 20, or (A1 depth)/DP < 0.8.
- 426 Following genotype quality control, we conducted variant-level quality control. First, we filtered variants
- 427 in the low complexity region or outside of the target region
- 428 (broad_custom_exome_v1.Homo_sapiens_assembly38.bed) with 50bp flanks. We excluded i)
- 429 monomorphic variants and, ii) variants with high missing rate (>10%). Using a quality-controlled variant
- 430 set, we conducted sample-level quality control. We collected sample QC metric by Hail's sample_qc
- 431 function. We implemented five hard filters (percent chimeric reads, percent contamination, call rate,
- 432 mean depth, and mean genotyping quality, Supplemental Information Figure 8) and four soft filters
- 433 (number of singletons, Ts/Tv ratio, Het/Hom variant ratio, and Insertion/Deletion ratio, Supplemental
- 434 Information Figure 9). For soft filters, we obtained residuals of metrics regressing by the first ten genetic
- 435 PCs and excluded +/- 4SD outliers. Finally, using only unrelated quality-controlled samples, we
- 436 computed Hardy-Weinberg P-values by continental ancestry estimated from genotyping data. Hardy-
- 437 Weinberg P-values in chromosome X was computed only for Female participants. We excluded
- 438 variants with ancestry-wise Hardy-Weinberg *P*-values $< 1 \times 10^{-6}$ or monomorphic variant. After quality
- control steps, 7,895,027 variants in 22 autosomes and chromosome X were found in 50,625 individuals
 remained.

441 Relatedness inference

442 We utilized the pc_relate⁷⁴ function from Hail to adjust for the presence of an admixed population within 443 the MGBB, using 91,615 pruned, common (MAF > 1%) variants that are located outside the major

- 444 histocompatibility complex (chromosome 6 24,000,000 37,000,000 base pair). Among 53,306
- individuals, we identified 3,147 pairs with a kinship greater than 0.0884.

446 Derivation of genetic principal components

- 447 To obtain insights utilizing reference populations, first we combined array genotypes from unrelated
- 448 MGBB participants with recently generated whole genome sequence datasets from ancestrally diverse
- 449 populations including 3,381 individuals from 1KG and HGDP²⁸. We intersected 495,213 autosomal,
- 450 non-palindromic variants outside the high LD region with minor allele counts \geq 10. After merging two
- 451 datasets, we pruned variants by PLINK2 software⁷¹ with –indep-pairwise option 1000 100 0.2 resulting
- in 257,754 variants. Using these genotypes, we derived the weight for each variant for PCs excluding
- 453 related samples. Using derived weights, we calculated 30 PCs for all the individuals from MGBB, 1KG,
- 454 and HGDP which were used in subsequent analysis.

455 **Fixation index**

- 456 Pairwise Fixation indices (*F*_{ST}) were computed among in MGBB-, 1KG- and HGDP- populations using
- 457 PLINK2 software. The phylogenetic tree was constructed neighbor-joining method⁷⁵ implemented by
- 458 ape R package⁷⁶.

459 **ADMIXTURE analysis**

460 Using PCs derived above, we conducted admixed component analysis using ADMIXTURE software 461 (version 1.3.0)²⁹. We optimized the number of admix component K from 1 to 20 and found that K = 10 462 showed the least cross-validation error (Supplemental Information Figure 3).

463 Genetic ancestral clustering

- To derive fine-scale genetic clusters in the population, we conducted Graph-based clustering which is
- 465 frequently used in single-cell RNA-seq clustering analysis implemented in Seurat software (version
- 466 4.1.0)²⁵. Though Seurat is primarily tailored for single-cell RNA seq data analyses, we leveraged its
- robust clustering capabilities for genetic ancestry clustering. Using the first 30 PCs derived above, we
- 468 constructed a nearest-neighbor graph and classified individuals into distinct clusters using the Louvain
- algorithm, a default clustering approach in Seurat with resolution parameter of 0.2. As Seurat identified
 the clusters in an unsupervised mode, we used individuals from the 1KG or HGDP as a "spike in"
- 470 the clusters in an unsupervised mode, we used individuals from the 1KG or HGDP as a "spike in"
- 471 positive controls (true labels).

472 Effective population size estimation

- 473 To estimate the effective population size using haplotype sharing information, we used IBDNe in
- 474 combination with the hap-ibd. First, we phased the genotypes of unrelated MGBB participants with

- 475 SHAPEIT software (version 4.2). Then, using hap-ibd software (version 1.0, 15Jun23.92f)⁷⁷, we
- 476 calculated IBD sharing, and this output was fed into IBDNe software (version 23Apr20)⁷⁸ to determine
- 477 the effective population size for each ancestry. To compare the effective population size trajectories in
- 478 British population in UK and MGBB, we computed effective population size in down-sampled, unrelated
- 479 UKBB European-like population to the same sample size as MGBB British-like population (n=11,508),
- 480 using microarray-based genotypes.

481 Variant annotation

- 482 We annotated WES data using the VEP software (version 107)⁷⁹, supplemented with the Loftee³⁰ and
- 483 dbNFSP⁸⁰ plugins. The "—pick" option was enabled to prioritize the canonical transcript. Additionally,
- 484 in-silico predictions from dbNFSP (version 4.2) were employed to prioritize missense variants.

485 **Pathogenic variant annotation**

- 486 We downloaded ClinVar database^{45,46} on Aug 16, 2022, and annotated all the variants identified by
- 487 exome sequence using snpEff software (version 5.0e)⁸¹. We identified 536,729 variants registered in
- 488 the ClinVar Database overall. To identify the carriers of pathogenic/likely pathogenic variants in the
- 489 ACMG SF v3.1 actionable genes^{43,44}, we only used variants with review status
- 490 "reviewed_by_expert_panel", "criteria_provided,_multiple_submitters,_no_conflicts"

491 Polygenic risk score

- Using the PRS-CS software⁸², we determined posterior weights for 1.2 million hapmap3 SNPs from a
 previous CAD GWAS⁴², which did not include the MGBB/UKBB population. Given our study's
- 494 predominant European population, we utilized the European reference panel provided by the PRS-CS
- 495 authors. Our model training and derivation of posterior weights incorporated parameters phi ranging
- 496 from 1×10^{-1} , 1×10^{-2} , 1×10^{-3} , 1×10^{-4} , and 1×10^{-5} . With these weights, we determined the CAD-
- 497 PRS for both UKBB and MGBB populations. From the UKBB results, we identified the optimal
- 498 parameter phi as $1 \times 1 \times 10^{-3}$ and applied this PRS in the MGBB analysis.

499Disease Phenotyping

- 500 We obtained patient data from the electronic health record system within the MGB network. We
- 501 specifically extracted ICD9 and ICD10 codes assigned to each patient. To enhance the interpretability
- 502 and powered analysis of the disease outcome, we employed the PheWAS R package (version 1.2)⁸³ to
- 503 map these codes to corresponding PheCodes²⁴. The PheWAS package utilizes a comprehensive
- 504 catalog of PheCodes (https://phewascatalog.org/phecodes). This mapping process facilitated a more
- 505 standardized and consistent representation of the patient's conditions for subsequent analyses. To

- 506 determine the prevalence or incidence of diseases, we considered the date of blood draw for
- 507 genotyping as the reference date. By aligning with the corresponding date of PheCodes occurrences,
- 508 we identified the prevalent or incident outcomes related to the date of enrollment in MGBB.

509 Clinical risk, genetic risk, and social risk for CAD

510 For the CAD analysis, we calculated the 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk

- 511 scores based on the PCE using the *PooledCohort* R package^{39,40,84}. The PCE accounts for sex, race,
- 512 age, total and HDL cholesterol, systolic blood pressure, antihypertensives prescription, current smoking,
- 513 and prevalence of diabetes mellitus. For missing values, we performed multiple imputation by chained
- 514 equations using the *mice* R package⁸⁵, using enrollment age, sex, and race as predictors. Among
- 515 participants without prior CAD, the first post-enrollment CAD incidence was ascertained based on
- 516 relevant ICD-9 and ICD10 codes from in-hospital records. We assessed the individual association of
- 517 10-year ASCVD risk, CAD-PRS, and SDI with incident CAD based on logistic regression.

518 **Exome-wide burden test**

- 519 We conducted a rare variant aggregation burden test implemented in Regenie software (version
- 520 3.2.5)⁸⁶. We generated masks comprised of predicted loss of function (high confidence by Loftee
- 521 software³⁰) and damaging missense variants predicted by > 90% of 29 in-silico prediction programs
- 522 included in dbNFSP (version 4.2)⁸⁰ with MAF < 0.01.

523 Genome-wide, phenome-wide association study

- 524 We conducted single variant PheWAS using imputed genotypes and 1,461 PheCodes. We applied mixed model approach implemented in Regenie software (version 3.2.5)⁸⁶. Null model was fit using 525 526 pruned common variants derived from microarray-derived genotypes (MAF > 1%, pruned by PLINK2 527 software⁷¹ with option –indep-pairwise 1000 100 0.9). The analyses were conducted ancestry wise. For 528 sex specific endpoint, only male or female were included in the analysis. The genome-wide significant threshold was set at $P = 1.6 \times 10^{-11}$ dividing conventional genome-wide significant threshold 5×10^{-8} by 529 3,048 tested phenotypes across three ancestries. To define the associated loci, we added the flanking 530 531 region (\pm 500,000 base-pairs) for all the variants with genome-wide significance (P < 1.6 x 10⁻¹¹) and
- 532 merged all overlapping regions.

533 **PheWAS Inflation statistics**

534 We estimated Lambda GC (observed chi-squared value divided by expected value) i) at top 1.0

535 percentile of the test statistics for rare variant burden PheWAS, and ii) using HapMap3 SNPs for

common variant PheWAS. For common variant PheWAS, LD score regression⁸⁷ was additionally
 performed to estimate intercept using ldscr R package (https://github.com/mglev1n/ldscr).

538 Geocoding

The participants' current address data was geocoded using the DeGAUSS framework⁸⁸, a collection of geospatial tools designed for cleaning and formatting geographic data. This process converts the address information into standardized spatial data, specifically latitude and longitude coordinates. Our analysis focused on participants residing in Massachusetts. We excluded 1) Participants whose addresses were located outside of the state of Massachusetts, 2) Participants for whom the geocoding process failed. We successfully geocoded 48,369 individuals with genotype data.

545 Area-based deprivation score index

546 For individuals whose addresses were successfully geocoded, we proceeded with the following steps: 547 A) We assigned each individual's address to a corresponding U.S. Census tract. Census tracts are 548 small, relatively stable geographic areas that are defined by the United States Census Bureau. They 549 are designed to be relatively homogeneous units with respect to population characteristics, economic 550 status, and living conditions, B) We then merged this Census tract-level data with SDI (2018 SDI. downloaded from https://www.graham-center.org/maps-data-tools/social-deprivation-index.html)⁵⁴. SDI 551 552 is a composite measure of area level deprivation based on seven demographic characteristics collected 553 in the American Community Survey (ACS) and used to quantify the socio-economic variation in 554 health outcomes. The final SDI is a composite measure of seven demographic characteristics collected 555 in the ACS: percent living in poverty, percent with less than 12 years of education, percent single-556 parent households, the percentage living in rented housing units, the percentage living in the 557 overcrowded housing unit, percent of households without a car, and percentage non-employed adults 558 under 65 years of age. This approach allows for a detailed, regional census tract-level analysis of the 559 social conditions experienced by the study participants.

560 **Spatial enrichment analysis**

We utilized the Bernoulli model in SaTScan⁸⁹. Under this model, individuals belonging to a specific genetic cluster were treated as "cases," while all other individuals were treated as "controls." This model compares the rates of cases in different areas to determine if the rate of cases inside the potential cluster area is significantly different from outside. To avoid detecting overly large and potentially less meaningful clusters, we limited our scan by setting the maximal diameter of the spatial cluster window. Specifically, we restricted this to a maximum radius of 4 kilometers.

567 Data availability

22

- 568 Genotyping and exome sequencing data for 13,500 participants from the MGBB are available in dbGAP
- 569 (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002018.v1.p1).
- 570 Additional MGBB data were accessed under institutional review board protocol for this current study
- 571 and are not publicly available due to restrictions on the data. The summary statistics for phenome-wide
- 572 common/rare variant association analysis and the allele frequencies of genetic clusters will be publically
- 573 available upon the publication.

574 Acknowledgements

575 **Funding sources**

576 S.K. is supported by Japan Society for the Promotion of Science (202160643), Uehara Memorial 577 Foundation, and National Institute of Health (NIH), National Heart Lung and Blood Institute (NHLBI, 578 K99HL169733). K.P is supported by the MGH Executive Committee for Research Fund for Medical 579 Discovery. S.J.C. is supported by a grant of the Korea Health Technology R&D Project through the 580 Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare. 581 Republic of Korea (HI19C1330). S.M.U. is supported by NIH National Human Genetics Research 582 Institute (NHGRI, T32HG010464). R.C.G. is supported by NIH (HG009922, OD026553, HL143295, 583 TR003201). B.M.N. is supported by R37MH107649. P.T.E. is supported by grants from the NIH 584 (1R01HL092577, 1R01HL157635, 5R01HL139731), from the American Heart Association 585 (18SFRN34230127, 961045), and from the European Union (MAESTRIA 965286). J.W.S. is supported 586 by OT2OD026553, U01HG008685, MH118233. M.L. is supported by grants from the NIH 587 (OT2OD002750, R01HL143295, U01HG008685, U01TR003201, and U24HG006834). E.K. is 588 supported by grants from the NIH (OT2OD026553, U01HG008685, P30 AR070253, OT2HL161841). 589 A.R.M. and Y.W. are supported by NIH, NHGRI (K99/R00MH117229 to A.R.M.) and by European 590 Union's Horizon 2020 research and innovation program under grant agreement 101016775. A.R.M. is 591 also supported by U01HG011719. P.N. is supported by grants from the NHLBI (R01HL127564), and NHGRI (U01HG011719). 592

593 **Declaration of interests**

594 K.P. reports research grants, paid to her institution, from Allelica, Apple, Amgen, AstraZeneca, Boston 595 Scientific, Genentech / Roche, and Ionis, R.C.G. has received compensation for advising the following 596 companies: Allelica, Atria, Fabric, Genome Web, Genomic Life and Juniper Genomics; and is co-597 founder of Genome Medical and Nurture Genomics, M.J.D is a founder of Maze Therapeutics and is a 598 member of the scientific advisory board for Neumora Therapeutics, Inc. (formerly known as RBNC 599 Therapeutics). B.M.N. is a member of the scientific advisory board at Deep Genomics and Neumora 600 Therapeutics, Inc. J.W.S. is a member of the Scientific Advisory Board of Sensorium Therapeutics (with 601 equity), and has received grant support from Biogen, Inc. P.T.E. receives sponsored research support 602 from Bayer AG, IBM Research, Bristol Myers Squibb, Pfizer and Novo Nordisk; he has also served on 603 advisory boards or consulted for MyoKardia and Bayer AG. J.W.S. is PI of a collaborative study of the 604 genetics of depression and bipolar disorder sponsored by 23andMe for which 23andMe provides 605 analysis time as in-kind support but no payments. P.N. reports research grants from Allelica, Apple, 606 Amgen, Boston Scientific, Genentech / Roche, and Novartis, personal fees from Allelica, Apple,

24

- 607 AstraZeneca, Blackstone Life Sciences, Eli Lilly & Co, Foresite Labs, Genentech / Roche, GV,
- 608 HeartFlow, Magnet Biomedicine, and Novartis, scientific advisory board membership of Esperion
- 609 Therapeutics, Preciseli, and TenSixteen Bio, scientific co-founder of TenSixteen Bio, equity in MyOme,
- 610 Preciseli, and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all unrelated to the
- 611 present work.

612 Author contributions

- 613 R.C.G., M.J.D., B.M.N., P.T.E., E.W.K., A.R.M., and P.N. conceptualized this project. S.K., K.P., S.J.C.,
- and E.W.K. curated phenotype data. S.K., and M.S.L. curated genotype data. S.K., M.U., and S.M.U.
- analyzed data. S.K., Y.W., P.T.E., E.W.K., A.R.M., and P.N. interpreted data. S.K., A.R.M., and P.N.
- prepared the initial draft. Y.W., K.P., M.U., S.J.C., W.E.H., R.C.G., M.J.D., B.M.N., P.T.E., J.W.S.,
- 617 E.W.K., A.R.M., and P.N. provided critical review and edits for the manuscript. S.H., W.E.H., R.C.G.,
- M.J.D., B.M.N., P.T.E., E.W.K., A.R.M., and P.N. supervised the project. S.H., W.E.H., P.T.E., J.W.S.,
- M.S.L., and E.W.K. managed the project administration. P.T.E., J.W.S., M.S.L., E.W.K., and P.N.
- 620 obtained funding for the project.

621 Figure Legends

622 Figure 1 | The cohort characteristics of MGBB

623 **a**, The columns represent the cumulative number of individuals who have consented to the MGBB.

624 Colors indicate the vital status of participants as of May 2023. **b**, Gender/Age at Consent Distribution:

- 625 The columns represent the distribution of the participants based on gender and age at the time of
- 626 consent. The individuals older than 100 years at the time of consent are not included in the displayed
- 627 numbers. **c**, Encounter patterns in the MGB Network. The number of encounters that participants have
- had within the MGB network. Please note that these encounters include sites where recruitment did not
- take place. **d**, Distribution of PheCodes based outcomes. The columns indicate the number of
- 630 outcomes in PheCode-category. Colors distinguish between incident and prevalent cases. MGH,
- Massachusetts General Hospital; BWH, Brigham's and Women's Hospital, MEEI Mass Eye and Ear
- 632 Institute; FH Faulkner Hospital; NWH, Newton-Wellesley Hospital; DFCI, Dana-Farber Cancer Institute.

633 Figure 2 | Fine-scale genetic clusters within MGBB

634 **a**, and **b**, UMAP representation of genetic clusters in MGBB. Each dot represents a participant, with

- 635 colors indicating distinct genetic clusters identified through graph-based clustering from genetic
- 636 principal components (Methods). The numbers indicate cluster identification. The color legend and
- 637 detailed cluster information will be found in Supplemental Table 2 and Figure S2. **c**, Population
- 638 differentiation in MGBB revealed by ADMIXTURE analysis. The heatmap displays the proportions of
- 639 ADMIXTURE components (K = 10) within each genetic cluster. The columns at the top of the heatmap
- represent the number of MGBB participants in each cluster. UMAP, Uniform Manifold Approximation
- and Projection; MGBB, Mass General Brigham Biobank

642 Figure 3 | Geospatial distribution, socioeconomic status, and disease risks in MGBB

- a, Geographical enrichment of genetic ancestries in the greater Boston area. The circle indicates area
 of significant enrichment of corresponding genetic ancestries. b, We tested the association between the
 socioeconomic deprivation index (SDI) and 1,564 PheCodes based outcomes (Prevalence + Incidence)
 in 47,070 MGBB participants. The model was adjusted for age, sex, and the first ten genetic principal
 components. An association was considered statistically significant if *P*-value was less 3.2 × 10⁻⁵
- 648 (0.05/1,564). The color of bars indicated the direction of the effect of SDI (higher SDI suggests higher
- deprivation). **c**, The disease frequency (prevalence + incidence) by deprivation status and genetic
- ancestry. The color of bars indicated deprivation status (higher or lower than the median SDI).
- 651 Complication of Birth, Other and unspecified complications of birth; puerperium affecting management
- of mother (PheCode 654).

Figure 4 | Rare variant identification in the MGBB

- a, Distribution of the number of protein-truncating variants across genetic ancestries. Each dot
 represents a participant. The horizontal axis represents the genetic ancestries in the MGBB, while the
 vertical axis represents the number of protein-truncating alleles in each participant. b, Carrier counts of
- 657 pathogenic/likely pathogenic variants in ACMG actionable genes. The colors of the bars indicate the
- 658 mode of inheritance of the genes. **c**, Carrier frequency of individuals with pathogenic variants in ACMG
- 659 actionable genes, categorized by ancestry. The colors of the bars correspond to the continental
- ancestries. The dotted line represents the average frequency in the MGBB. **d**, Summary of phenome-
- wide gene burden testing in the MGBB. We conducted exome-wide phenome wide association analysis

across 1,454 PheCodes based outcomes in 14,912 genes. The columns indicate the number of significant associations ($P < 1.8 \times 10^{-9} = 5 \times 10^{-2}/28,035,307$ phenotype-transcript pairs) for designated genes. The color of each column corresponds to the associated PheCode-category. MGBB, Mass General Brigham Biobank; ACMG, American College of Medical Genetics and Genomics; pLOF, predicted loss of function; AFR, African; AMR, Admixed-American; EAS, East Asian; EUR, European; SAS, South Asian.

668 Figure 5 | Common variant association study in the MGBB

669 a, Number of associations in the common variant phenome-wide association analysis in MGBB. We conducted associations between common genetic variants (Minor allele counts \geq 40) and 670 1,461 PheCodes (Case counts \geq 60), categorized by continental ancestries (AFR. n = 2.846: 671 672 AMR, n = 3,756; EUR, n = 44,163). The columns represent the number of significant associations ($P < 1.6 \times 10^{-11}$) on each chromosome. The color indicates the ancestry in which 673 the association was observed. We annotated chromosomes with more than 10 associations, 674 675 indicating the representative locus in the chromosome. **b**, Manhattan plot of GWAS for Rhesus 676 isoimmunization during pregnancy in women (n = 23.959). The horizontal axis displays the genomic coordinates from chromosome 1 to chromosome X. The vertical axis represents the 677 strength of association in negative log₁₀ *P*-value. The significantly associated variants in the 678 *RHD* locus is highlighted. **c**, Odds ratio for Rhesus isoimmunization during pregnancy by 679 680 rs72660908 genotypes. The dots and error bars represent the estimated odds ratios and 95% confidence intervals compared to the reference homozygotes ([C/C]). **d**, *RHD* read counts from 681 Whole Blood RNA sequence data obtained from the GTEx dataset. The horizontal axis 682 displays the number of reads aligned to the RHD gene, categorized by rs72660908 genotypes. 683 e, Frequencies of rs72660908 homozygotes across genetic clusters in MGBB. The horizontal 684 685 axis corresponds to the genetic ancestries in MGBB, while the vertical axis represents the ancestral frequency of rs72660908 homozygotes ([G/G]). The colors of the columns 686 correspond to continental ancestries. MGBB, Mass General Brigham Biobank; ACMG, 687 688 American College of Medical Genetics and Genomics; pLOF, predicted loss of function; AFR, 689 African; AMR, Admixed-American; EAS, East Asian; EUR, European; SAS, South Asian; 690 GWAS, Genome-Wide Association Study; GTEx, Genotype-Tissue Expression.

691 Supplemental Figure Legends

692 Figure S1 | Projection of the fine genetic clusters in the continental ancestry space

693 a, The distribution of the continental ancestries in the UMAP space. Each point on the plot represents 694 an individual participant of MGBB. To infer the continental ancestry of each participant, we utilized the 695 K-nearest neighbor algorithm trained on the 1000 Genomes Project dataset. The colors assigned to the 696 points represent the inferred continental ancestries. The horizontal axis corresponds to the first axis of 697 the UMAP projection, and the vertical axis represents the second axis. This two-dimensional 698 representation allows us to visualize the clustering and distribution patterns of different continental 699 ancestries within the MGBB population. **b**, The distribution of the fine-scale genetic clusters in the 700 MGBB on conventional PC space. Each point on the plot represents an individual in MGBB. The colors 701 assigned to the points represent genetic clusters inferred by the network-based clustering method 702 (Methods). The horizontal axis corresponds to the first genetic PC, and the vertical axis represents the 703 second genetic PC. UMAP, Uniform Manifold Approximation and Projection; MGBB, Mass General

704 Brigham Biobank; PC, principal component.

705 Figure S2 | Enrichment of the reference groups in the genetic clusters inferred in MGBB

The horizontal axis shows reference populations from 1000 Genomes Project and Human Genome Diversity Project. The vertical axis shows genetic clusters inferred from MGBB. In the left panel, the heights of bars show the number of MGBB participants included in the genetic clusters. In the right panel, the size and transparency of rectangle shows intersection size between reference population and genetic clusters. The number of individuals in the clusters and the color legend are found in Supplemental Table 2. Abbreviations for reference populations will be find in Supplemental Table 7.

712 MGBB, Mass General Brigham Biobank.

713 Figure S3 | ADMIXTURE analysis for reference population (1KG + HGDP) and genetic clusters

714 a, Phylogenetic tree generated using F st Values. The phylogenic tree was constructed using the 715 Neighbor-Joining method with pairwise Fst values serving as a measure of genetic distance between 716 populations. A higher Fst value indicates a greater genetic differentiation between populations. The 717 numeric numbers indicate genetic cluster in MGBB. Ancestry names indicated reference populations in 718 1KG or HGDP. The number indicate genetic clusters in MGBB. b, In each panel, a stacked column of 719 color segments represents an individual participant. The color of each segment corresponds to one of 720 the K = 10 ancestral components, as determined by ADMIXTURE software. The length of each colored 721 segment within a participant's column indicates the estimated proportion of their genome attributed to 722 that specific ancestral population. The choice of K = 10 was informed by cross-validation results, with 723 the aim of minimizing prediction error (Supplemental Information Figure 3). The abbreviations and 724 detailed descriptions for the ancestral populations corresponding to each color are provided in 725 Supplemental Table 7. 1KG, 1000 Genomes Project; HGDP, Human Genome Diversity Project; MGBB, 726 Mass General Brigham Biobank.

727 Figure S4 | Phenome wide association analysis for cluster 4

Each dot represents the association results based on PheCodes. We examined the relationship

- between membership in genetic cluster 4 of the MGBB biobank and PheCodes outcomes. This
- association was assessed using a logistic regression model, adjusted for age and sex. MGBB, Mass
- 731 General Brigham Biobank.

732 Figure S5 | Shared founder mutations across genetic clusters 4, 11, and 14

- The left panels are showing the distribution of genetic cluster 4, 11, and 14 in the UMAP space. The
- right panel shows the distribution of Ashkenazi founder mutations described in the previous literatures.
- The horizontal axes show the genetic clusters identified in MGBB, and the vertical axes show the allele
- frequencies determined by whole exome sequencing of MGBB by the genetic clusters. UMAP, Uniform
- 737 Manifold Approximation and Projection; MGBB, Mass General Brigham Biobank.

738 Figure S6 | Effective population sizes in the genetic clusters in MGBB

- 739 The horizontal axes show generations ago. The vertical axes show the estimated population size.
- Numbers on the top of panels show the cluster identification. The black lines show the estimates and aray lines show 95% confidence interval.

742 Figure S7 | Geographical, socioeconomical, distributions of genetic clusters

- 743 Distributions of socioeconomic (**a**), clinical (**b**), and genetic risks (**c**). Each dot indicates MGBB
- 744 participants. The horizontal axes show genetic cluster. SDI, social deprivation index; PCE, pooled
- cohort equation, CAD PRS, polygenic risk score for coronary artery disease.

746 Figure S8 | Social deprivation in Massachusetts and Greater Boston Area

- 747 The color of each grid represents the median Social Deprivation Index (SDI) of the participants from
- 748 MGBB. A darker shade denotes a higher level of socioeconomic deprivation. Grids with fewer than five
- 749 participants have been excluded.

750 Figure S9 | Different annotation rate for the functional variants in the pathogenic genes

- 751 **a,** The bar heights depict the proportion of pLOF variants in ACMG genes within specific genetic
- 752 clusters identified in MGBB with pathogenic/likely pathogenic annotations as determined by multiple
- 753 expert reviews in ClinVar. **b**, The odds ratio indicates the likelihood of pLOF variants in ACMG genes
- having pathogenic/likely pathogenic annotations based on multiple expert reviews. The results are
- 755 presented in the continental ancestries and in reference to the European population. Error bars indicate
- 95% confidence intervals. OR, Odds Ratio; AFR, African; AMR, Admixed American; EAS, East Asian;
- 757 EUR, European; SAS, South Asian. ACMG, American College of Medical Genetics and Genomics;
- 758 MGBB, Mass General Brigham Biobank; pLOF predicted loss of function.

759 Figure S10 | Penetrant association of rs334 for sickle cell anemia

- 760 **a**, The prevalence of Sickle cell anemia by rs334 genotypes. **b**, The RBC measurements in the MGB
- 761 participants by combined genotype of rs33930165 and rs334. The box plot depicts the first and third
- quartiles, with the line inside the box indicating the median value. RBC, Red Blood Cell count.

763 References

- 7641.Townsend, P., Phillimore, P., and Beattie, A. (1988). Health and Deprivation: Inequality and the765North (Routledge).
- Li, X., Memarian, E., Sundquist, J., Zöller, B., and Sundquist, K. (2014). Neighbourhood Deprivation, Individual-Level Familial and Socio-Demographic Factors and Diagnosed Childhood Obesity: A Nationwide Multilevel Study from Sweden. Obesity Facts 7, 253-263. 10.1159/000365955.
- Bann, D., Johnson, W., Li, L., Kuh, D., and Hardy, R. (2018). Socioeconomic inequalities in
 childhood and adolescent body-mass index, weight, and height from 1953 to 2015: an analysis of
 four longitudinal, observational, British birth cohort studies. Lancet Public Health *3*, e194-e203.
 10.1016/S2468-2667(18)30045-8.
- Fan, J.X., Wen, M., and Li, K. (2020). Associations between obesity and neighborhood
 socioeconomic status: Variations by gender and family income status. SSM Popul Health *10*,
 100529. 10.1016/j.ssmph.2019.100529.
- Akiyama, M., Okada, Y., Kanai, M., Takahashi, A., Momozawa, Y., Ikeda, M., Iwata, N., Ikegawa, S.,
 Hirata, M., Matsuda, K., et al. (2017). Genome-wide association study identifies 112 new loci for
 body mass index in the Japanese population. Nat Genet *49*, 1458-1467. 10.1038/ng.3951.
- Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A., Vukcevic, D.,
 Delaneau, O., O'Connell, J., et al. (2018). The UK Biobank resource with deep phenotyping and
 genomic data. Nature *562*, 203-209. 10.1038/s41586-018-0579-z.
- 782 7. Zhou, W., Kanai, M., Wu, K.H., Rasheed, H., Tsuo, K., Hirbo, J.B., Wang, Y., Bhattacharya, A., Zhao,
 783 H., Namba, S., et al. (2022). Global Biobank Meta-analysis Initiative: Powering genetic discovery
 784 across human disease. Cell Genom *2*, 100192. 10.1016/j.xgen.2022.100192.
- Kurki, M.I., Karjalainen, J., Palta, P., Sipila, T.P., Kristiansson, K., Donner, K.M., Reeve, M.P.,
 Laivuori, H., Aavikko, M., Kaunisto, M.A., et al. (2023). FinnGen provides genetic insights from a
 well-phenotyped isolated population. Nature *613*, 508-518. 10.1038/s41586-022-05473-8.
- Belbin, G.M., Cullina, S., Wenric, S., Soper, E.R., Glicksberg, B.S., Torre, D., Moscati, A., Wojcik,
 G.L., Shemirani, R., Beckmann, N.D., et al. (2021). Toward a fine-scale population health monitoring
 system. Cell *184*, 2068-2083 e2011. 10.1016/j.cell.2021.03.034.
- Verma, A., Damrauer, S.M., Naseer, N., Weaver, J., Kripke, C.M., Guare, L., Sirugo, G., Kember,
 R.L., Drivas, T.G., Dudek, S.M., et al. (2022). The Penn Medicine BioBank: Towards a GenomicsEnabled Learning Healthcare System to Accelerate Precision Medicine in a Diverse Population. J
 Pers Med *12*. 10.3390/jpm12121974.
- Brumpton, B.M., Graham, S., Surakka, I., Skogholt, A.H., Loset, M., Fritsche, L.G., Wolford, B., Zhou,
 W., Nielsen, J.B., Holmen, O.L., et al. (2022). The HUNT study: A population-based cohort for
 genetic research. Cell Genom *2*, 100193. 10.1016/j.xgen.2022.100193.
- 79812.Johnson, R., Ding, Y., Bhattacharya, A., Knyazev, S., Chiu, A., Lajonchere, C., Geschwind, D.H.,799and Pasaniuc, B. (2023). The UCLA ATLAS Community Health Initiative: Promoting precision health800research in a diverse biobank. Cell Genom 3, 100243. 10.1016/j.xgen.2022.100243.
- 13. Zawistowski, M., Fritsche, L.G., Pandit, A., Vanderwerff, B., Patil, S., Schmidt, E.M., VandeHaar, P.,
 Willer, C.J., Brummett, C.M., Kheterpal, S., et al. (2023). The Michigan Genomics Initiative: A
 biobank linking genotypes and electronic clinical records in Michigan Medicine patients. Cell Genom
 3, 100257. 10.1016/j.xgen.2023.100257.
- Soria, L.F., Ludwig, E.H., Clarke, H.R., Vega, G.L., Grundy, S.M., and McCarthy, B.J. (1989).
 Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100.
 Proceedings of the National Academy of Sciences *86*, 587-591. 10.1073/pnas.86.2.587.

- Shen, H., Damcott, C.M., Rampersaud, E., Pollin, T.I., Horenstein, R.B., McArdle, P.F., Peyser, P.A.,
 Bielak, L.F., Post, W.S., Chang, Y.-P.C., et al. (2010). Familial Defective Apolipoprotein B-100 and
 Increased Low-Density Lipoprotein Cholesterol and Coronary Artery Calcification in the Old Order
 Amish. Archives of Internal Medicine *170*. 10.1001/archinternmed.2010.384.
- Cohen, J.C., Boerwinkle, E., Mosley, T.H., and Hobbs, H.H. (2006). Sequence Variations in*PCSK9*,
 Low LDL, and Protection against Coronary Heart Disease. New England Journal of Medicine *354*,
 1264-1272. 10.1056/nejmoa054013.
- 815 17. Cohen, J., Pertsemlidis, A., Kotowski, I.K., Graham, R., Garcia, C.K., and Hobbs, H.H. (2005). Low
 816 LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in
 817 PCSK9. Nature Genetics *37*, 161-165. 10.1038/ng1509.
- 818
 18. Luzzatto, L., Ally, M., and Notaro, R. (2020). Glucose-6-phosphate dehydrogenase deficiency. Blood
 819
 136, 1225-1240. 10.1182/blood.2019000944.
- Manrai, A.K., Funke, B.H., Rehm, H.L., Olesen, M.S., Maron, B.A., Szolovits, P., Margulies, D.M.,
 Loscalzo, J., and Kohane, I.S. (2016). Genetic Misdiagnoses and the Potential for Health Disparities.
 New England Journal of Medicine *375*, 655-665. 10.1056/nejmsa1507092.
- Aragam, K.G., Dobbyn, A., Judy, R., Chaffin, M., Chaudhary, K., Hindy, G., Cagan, A., Finneran, P.,
 Weng, L.C., Loos, R.J.F., et al. (2020). Limitations of Contemporary Guidelines for Managing
 Patients at High Genetic Risk of Coronary Artery Disease. J Am Coll Cardiol *75*, 2769-2780.
 10.1016/j.jacc.2020.04.027.
- Baharian, S., Barakatt, M., Gignoux, C.R., Shringarpure, S., Errington, J., Blot, W.J., Bustamante,
 C.D., Kenny, E.E., Williams, S.M., Aldrich, M.C., and Gravel, S. (2016). The Great Migration and
 African-American Genomic Diversity. PLOS Genetics *12*, e1006059. 10.1371/journal.pgen.1006059.
- Han, E., Carbonetto, P., Curtis, R.E., Wang, Y., Granka, J.M., Byrnes, J., Noto, K., Kermany, A.R.,
 Myres, N.M., Barber, M.J., et al. (2017). Clustering of 770,000 genomes reveals post-colonial
 population structure of North America. Nat Commun *8*, 14238. 10.1038/ncomms14238.
- Bai, C.L., Vazifeh, M.M., Yeang, C.-H., Tachet, R., Wells, R.S., Vilar, M.G., Daly, M.J., Ratti, C., and
 Martin, A.R. (2020). Population Histories of the United States Revealed through Fine-Scale
 Migration and Haplotype Analysis. The American Journal of Human Genetics *106*, 371-388.
 10.1016/j.ajhg.2020.02.002.
- Barrier Strain Strain
- Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W.M., 3rd, Zheng, S., Butler, A., Lee, M.J., Wilk, A.J.,
 Darby, C., Zager, M., et al. (2021). Integrated analysis of multimodal single-cell data. Cell *184*, 3573-3587 e3529. 10.1016/j.cell.2021.04.048.
- Bergstrom, A., McCarthy, S.A., Hui, R., Almarri, M.A., Ayub, Q., Danecek, P., Chen, Y., Felkel, S.,
 Hallast, P., Kamm, J., et al. (2020). Insights into human genetic variation and population history from
 929 diverse genomes. Science 367. 10.1126/science.aay5012.
- Auton, A., Abecasis, G.R., Altshuler, D.M., Durbin, R.M., Abecasis, G.R., Bentley, D.R., Chakravarti,
 A., Clark, A.G., Donnelly, P., Eichler, E.E., et al. (2015). A global reference for human genetic
 variation. Nature *526*, 68-74. 10.1038/nature15393.
- 850 28. Koenig, Z., Yohannes, M.T., Nkambule, L.L., Goodrich, J.K., Kim, H.A., Zhao, X., Wilson, M.W., Tiao,
 851 G., Hao, S.P., Sahakian, N., et al. (2023). A harmonized public resource of deeply sequenced
 852 diverse human genomes. Cold Spring Harbor Laboratory.

- Alexander, D.H., Novembre, J., and Lange, K. (2009). Fast model-based estimation of ancestry in unrelated individuals. Genome Res *19*, 1655-1664. 10.1101/gr.094052.109.
- 855 30. Karczewski, K.J., Francioli, L.C., Tiao, G., Cummings, B.B., Alfoldi, J., Wang, Q., Collins, R.L.,
 856 Laricchia, K.M., Ganna, A., Birnbaum, D.P., et al. (2020). The mutational constraint spectrum
 857 quantified from variation in 141,456 humans. Nature *581*, 434-443. 10.1038/s41586-020-2308-7.
- Laken, S.J., Petersen, G.M., Gruber, S.B., Oddoux, C., Ostrer, H., Giardiello, F.M., Hamilton, S.R.,
 Hampel, H., Markowitz, A., Klimstra, D., et al. (1997). Familial colorectal cancer in Ashkenazim due
 to a hypermutable tract in APC. Nature Genetics *17*, 79-83. 10.1038/ng0997-79.
- 32. Levy-Lahad, E., Catane, R., Eisenberg, S., Kaufman, B., Hornreich, G., Lishinsky, E., Shohat, M.,
 Weber, B.L., Beller, U., Lahad, A., and Halle, D. (1997). Founder BRCA1 and BRCA2 mutations in
 Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breastovarian cancer families. Am J Hum Genet *60*, 1059-1067.
- Salmela, E., Lappalainen, T., Fransson, I., Andersen, P.M., Dahlman-Wright, K., Fiebig, A., Sistonen,
 P., Savontaus, M.L., Schreiber, S., Kere, J., and Lahermo, P. (2008). Genome-wide analysis of
 single nucleotide polymorphisms uncovers population structure in Northern Europe. PLoS One *3*,
 e3519. 10.1371/journal.pone.0003519.
- 869 34. Huyghe, J.R., Fransen, E., Hannula, S., Van Laer, L., Van Eyken, E., Maki-Torkko, E., Aikio, P.,
 870 Sorri, M., Huentelman, M.J., and Van Camp, G. (2011). A genome-wide analysis of population
 871 structure in the Finnish Saami with implications for genetic association studies. Eur J Hum Genet *19*,
 872 347-352. 10.1038/ejhg.2010.179.
- 873 35. Lazaridis, I., Patterson, N., Mittnik, A., Renaud, G., Mallick, S., Kirsanow, K., Sudmant, P.H.,
 874 Schraiber, J.G., Castellano, S., Lipson, M., et al. (2014). Ancient human genomes suggest three
 875 ancestral populations for present-day Europeans. Nature *513*, 409-413. 10.1038/nature13673.
- Baak, W., Lazaridis, I., Patterson, N., Rohland, N., Mallick, S., Llamas, B., Brandt, G., Nordenfelt, S.,
 Harney, E., Stewardson, K., et al. (2015). Massive migration from the steppe was a source for IndoEuropean languages in Europe. Nature *522*, 207-211. 10.1038/nature14317.
- 879 37. Carmi, S., Hui, K.Y., Kochav, E., Liu, X., Xue, J., Grady, F., Guha, S., Upadhyay, K., Ben-Avraham,
 880 D., Mukherjee, S., et al. (2014). Sequencing an Ashkenazi reference panel supports population881 targeted personal genomics and illuminates Jewish and European origins. Nature Communications *5*,
 882 4835. 10.1038/ncomms5835.
- 883
 884
 884
 885
 886
 887
 888
 885
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
 886
- Browning, S.R., Browning, B.L., Daviglus, M.L., Durazo-Arvizu, R.A., Schneiderman, N., Kaplan,
 R.C., and Laurie, C.C. (2018). Ancestry-specific recent effective population size in the Americas.
 PLoS Genet *14*, e1007385. 10.1371/journal.pgen.1007385.
- 40. Goff, D.C., Lloyd-Jones, D.M., Bennett, G., Coady, S., D'Agostino, R.B., Gibbons, R., Greenland, P.,
 40. Lackland, D.T., Levy, D., O'Donnell, C.J., et al. (2014). 2013 ACC/AHA Guideline on the
 41. Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American
 42. Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology
 43. 63, 2935-2959. https://doi.org/10.1016/j.jacc.2013.11.005.
- 41. Goff, D.C., Lloyd-Jones, D.M., Bennett, G., Coady, S., D'Agostino, R.B., Gibbons, R., Greenland, P.,
 Lackland, D.T., Levy, D., O'Donnell, C.J., et al. (2014). 2013 ACC/AHA Guideline on the
 Assessment of Cardiovascular Risk. Circulation *129*, S49-S73.
 10.1161/01.cir.0000437741.48606.98.
- 89842.A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery899disease. (2015). Nature Genetics 47, 1121-1130. 10.1038/ng.3396.

- 90043.Miller, D.T., Lee, K., Abul-Husn, N.S., Amendola, L.M., Brothers, K., Chung, W.K., Gollob, M.H.,
Gordon, A.S., Harrison, S.M., Hershberger, R.E., et al. (2022). ACMG SF v3.1 list for reporting of
secondary findings in clinical exome and genome sequencing: A policy statement of the American
College of Medical Genetics and Genomics (ACMG). Genetics in Medicine 24, 1407-1414.90410.1016/j.gim.2022.04.006.
- 90544.Miller, D.T., Lee, K., Chung, W.K., Gordon, A.S., Herman, G.E., Klein, T.E., Stewart, D.R., Amendola,
L.M., Adelman, K., Bale, S.J., et al. (2021). ACMG SF v3.0 list for reporting of secondary findings in
clinical exome and genome sequencing: a policy statement of the American College of Medical
Genetics and Genomics (ACMG). Genet Med 23, 1381-1390. 10.1038/s41436-021-01172-3.
- 45. Landrum, M.J., Lee, J.M., Benson, M., Brown, G.R., Chao, C., Chitipiralla, S., Gu, B., Hart, J.,
 910 Hoffman, D., Jang, W., et al. (2018). ClinVar: improving access to variant interpretations and
 911 supporting evidence. Nucleic Acids Res 46, D1062-D1067. 10.1093/nar/gkx1153.
- 46. Landrum, M.J., Lee, J.M., Riley, G.R., Jang, W., Rubinstein, W.S., Church, D.M., and Maglott, D.R.
 (2014). ClinVar: public archive of relationships among sequence variation and human phenotype.
 Nucleic Acids Res *42*, D980-985. 10.1093/nar/gkt1113.
- 47. Backman, J.D., Li, A.H., Marcketta, A., Sun, D., Mbatchou, J., Kessler, M.D., Benner, C., Liu, D.,
 biobank participants. Nature *599*, 628-634. 10.1038/s41586-021-04103-z.
- 91848.Jurgens, S.J., Choi, S.H., Morrill, V.N., Chaffin, M., Pirruccello, J.P., Halford, J.L., Weng, L.C.,919Nauffal, V., Roselli, C., Hall, A.W., et al. (2022). Analysis of rare genetic variation underlying920cardiometabolic diseases and traits among 200,000 individuals in the UK Biobank. Nat Genet 54,921240-250. 10.1038/s41588-021-01011-w.
- 922 49. Pilarski, R. (2019). PTEN Hamartoma Tumor Syndrome: A Clinical Overview. Cancers (Basel) *11*.
 923 10.3390/cancers11060844.
- 92450.Tischkowitz, M., Colas, C., Pouwels, S., Hoogerbrugge, N., Group, P.G.D., and European Reference925Network, G. (2020). Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour926syndrome. Eur J Hum Genet 28, 1387-1393. 10.1038/s41431-020-0651-7.
- 92751.Taliun, D., Harris, D.N., Kessler, M.D., Carlson, J., Szpiech, Z.A., Torres, R., Taliun, S.A.G., Corvelo,928A., Gogarten, S.M., Kang, H.M., et al. (2021). Sequencing of 53,831 diverse genomes from the929NHLBI TOPMed Program. Nature *590*, 290-299. 10.1038/s41586-021-03205-y.
- 52. Huang, L., Rosen, J.D., Sun, Q., Chen, J., Wheeler, M.M., Zhou, Y., Min, Y.-I., Kooperberg, C.,
 Conomos, M.P., Stilp, A.M., et al. (2022). TOP-LD: A tool to explore linkage disequilibrium with
 TOPMed whole-genome sequence data. The American Journal of Human Genetics *109*, 1175-1181.
 10.1016/j.ajhg.2022.04.006.
- 93453.Genetic effects on gene expression across human tissues. (2017). Nature 550, 204-213.93510.1038/nature24277.
- 93654.Butler, D.C., Petterson, S., Phillips, R.L., and Bazemore, A.W. (2013). Measures of social937deprivation that predict health care access and need within a rational area of primary care service938delivery. Health Serv Res 48, 539-559. 10.1111/j.1475-6773.2012.01449.x.
- 93955.Kimenai, D.M., Pirondini, L., Gregson, J., Prieto, D., Pocock, S.J., Perel, P., Hamilton, T., Welsh, P.,
Campbell, A., Porteous, D.J., et al. (2022). Socioeconomic Deprivation: An Important, Largely941Unrecognized Risk Factor in Primary Prevention of Cardiovascular Disease. Circulation 146, 240-
248. 10.1161/CIRCULATIONAHA.122.060042.
- Schultz, W.M., Kelli, H.M., Lisko, J.C., Varghese, T., Shen, J., Sandesara, P., Quyyumi, A.A., Taylor,
 H.A., Gulati, M., Harold, J.G., et al. (2018). Socioeconomic Status and Cardiovascular Outcomes:
 Challenges and Interventions. Circulation *137*, 2166-2178. 10.1161/CIRCULATIONAHA.117.029652.

- 57. Bann, D., Wright, L., Hardy, R., Williams, D.M., and Davies, N.M. (2022). Polygenic and
 socioeconomic risk for high body mass index: 69 years of follow-up across life. PLoS Genet *18*, e1010233. 10.1371/journal.pgen.1010233.
- 58. Cromer, S.J., Lakhani, C.M., Mercader, J.M., Majarian, T.D., Schroeder, P., Cole, J.B., Florez, J.C.,
 patel, C.J., Manning, A.K., Burnett-Bowie, S.M., Merino, J., and Udler, M.S. (2023). Association and
 Interaction of Genetics and Area-Level Socioeconomic Factors on the Prevalence of Type 2
 piabetes and Obesity. Diabetes Care *46*, 944-952. 10.2337/dc22-1954.
- 953 59. Mostafavi, H., Harpak, A., Agarwal, I., Conley, D., Pritchard, J.K., and Przeworski, M. (2020).
 954 Variable prediction accuracy of polygenic scores within an ancestry group. Elife *9*.
 955 10.7554/eLife.48376.
- 95660.He, Y., Qian, D.C., Diao, J.A., Cho, M.H., Silverman, E.K., Gusev, A., Manrai, A.K., Martin, A.R., and957958Patel, C.J. (2023). Prediction and stratification of longitudinal risk for chronic obstructive pulmonary958disease across smoking behaviors. medRxiv. 10.1101/2023.04.04.23288086.
- Martin, A.R., Kanai, M., Kamatani, Y., Okada, Y., Neale, B.M., and Daly, M.J. (2019). Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet *51*, 584-591.
 10.1038/s41588-019-0379-x.
- 962 62. Flegel, W.A. (2007). The genetics of the Rhesus blood group system. Blood Transfus *5*, 50-57.
 10.2450/2007.0011-07.
- 63. Lee, Y.H., Thaweethai, T., Sheu, Y.H., Feng, Y.A., Karlson, E.W., Ge, T., Kraft, P., and Smoller, J.W.
 (2023). Impact of selection bias on polygenic risk score estimates in healthcare settings. Psychol
 Med, 1-11. 10.1017/s0033291723001186.
- Boutin, N., Mathieu, K., Hoffnagle, A., Allen, N., Castro, V., Morash, M., O'Rourke, P., Hohmann, E.,
 Herring, N., Bry, L., et al. (2016). Implementation of Electronic Consent at a Biobank: An Opportunity
 for Precision Medicine Research. Journal of Personalized Medicine *6*, 17. 10.3390/jpm6020017.
- 65. Goldstein, J.I., Crenshaw, A., Carey, J., Grant, G.B., Maguire, J., Fromer, M., O'Dushlaine, C.,
 Moran, J.L., Chambert, K., Stevens, C., et al. (2012). zCall: a rare variant caller for array-based
 genotyping: genetics and population analysis. Bioinformatics 28, 2543-2545.
 10.1093/bioinformatics/bts479.
- 974
 66.
 Altschul, S.F., Gish, W., Miller, W., Myers, E.W., and Lipman, D.J. (1990). Basic local alignment

 975
 search tool. J Mol Biol 215, 403-410. 10.1016/s0022-2836(05)80360-2.
- Bas, S., Forer, L., Schonherr, S., Sidore, C., Locke, A.E., Kwong, A., Vrieze, S.I., Chew, E.Y., Levy,
 S., McGue, M., et al. (2016). Next-generation genotype imputation service and methods. Nat Genet
 48, 1284-1287. 10.1038/ng.3656.
- 97968.Loh, P.R., Palamara, P.F., and Price, A.L. (2016). Fast and accurate long-range phasing in a UK980Biobank cohort. Nat Genet 48, 811-816. 10.1038/ng.3571.
- 98169.Das, S., Forer, L., Schönherr, S., Sidore, C., Locke, A.E., Kwong, A., Vrieze, S.I., Chew, E.Y., Levy,982S., McGue, M., et al. (2016). Next-generation genotype imputation service and methods. Nature983Genetics 48, 1284-1287. 10.1038/ng.3656.
- Danecek, P., Auton, A., Abecasis, G., Albers, C.A., Banks, E., DePristo, M.A., Handsaker, R.E.,
 Lunter, G., Marth, G.T., Sherry, S.T., et al. (2011). The variant call format and VCFtools.
 Bioinformatics 27, 2156-2158. 10.1093/bioinformatics/btr330.
- 71. Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., and Lee, J.J. (2015). Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience *4*, 7.
 989 10.1186/s13742-015-0047-8.
- McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K.,
 Altshuler, D., Gabriel, S., Daly, M., and DePristo, M.A. (2010). The Genome Analysis Toolkit: a

- MapReduce framework for analyzing next-generation DNA sequencing data. Genome research 20,
 1297-1303. 10.1101/gr.107524.110.
- 994 73. The Hail Team. Hail. <u>https://github.com/hail-is/hail</u>.
- 99574.Conomos, M.P., Reiner, A.P., Weir, B.S., and Thornton, T.A. (2016). Model-free Estimation of996Recent Genetic Relatedness. Am J Hum Genet 98, 127-148. 10.1016/j.ajhg.2015.11.022.
- 99775.Saitou, N., and Nei, M. (1987). The neighbor-joining method: a new method for reconstructing998phylogenetic trees. Molecular Biology and Evolution 4, 406-425.99910.1093/oxfordjournals.molbev.a040454.
- 100076.Paradis, E., and Schliep, K. (2019). ape 5.0: an environment for modern phylogenetics and
evolutionary analyses in R. Bioinformatics *35*, 526-528. 10.1093/bioinformatics/bty633.
- 1002 77. Zhou, Y., Browning, S.R., and Browning, B.L. (2020). A Fast and Simple Method for Detecting
 1003 Identity-by-Descent Segments in Large-Scale Data. The American Journal of Human Genetics *106*,
 1004 426-437. 10.1016/j.ajhg.2020.02.010.
- 100578.Browning, S.R., and Browning, B.L. (2015). Accurate Non-parametric Estimation of Recent Effective1006Population Size from Segments of Identity by Descent. The American Journal of Human Genetics 97,1007404-418. 10.1016/j.ajhg.2015.07.012.
- 100879.McLaren, W., Gil, L., Hunt, S.E., Riat, H.S., Ritchie, G.R., Thormann, A., Flicek, P., and Cunningham,1009F. (2016). The Ensembl Variant Effect Predictor. Genome Biol *17*, 122. 10.1186/s13059-016-0974-4.
- 101080.Liu, X., Li, C., Mou, C., Dong, Y., and Tu, Y. (2020). dbNSFP v4: a comprehensive database of1011transcript-specific functional predictions and annotations for human nonsynonymous and splice-site1012SNVs. Genome Med *12*, 103. 10.1186/s13073-020-00803-9.
- 101381.Cingolani, P., Platts, A., Wang le, L., Coon, M., Nguyen, T., Wang, L., Land, S.J., Lu, X., and Ruden,1014D.M. (2012). A program for annotating and predicting the effects of single nucleotide polymorphisms,1015SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6,101680-92. 10.4161/fly.19695.
- 101782.Ge, T., Chen, C.Y., Ni, Y., Feng, Y.A., and Smoller, J.W. (2019). Polygenic prediction via Bayesian1018regression and continuous shrinkage priors. Nat Commun *10*, 1776. 10.1038/s41467-019-09718-5.
- 101983.Carroll, R.J., Bastarache, L., and Denny, J.C. (2014). R PheWAS: data analysis and plotting tools for1020phenome-wide association studies in the R environment. Bioinformatics *30*, 2375-2376.102110.1093/bioinformatics/btu197.
- 1022 84. Yadlowsky, S., Hayward, R.A., Sussman, J.B., McClelland, R.L., Min, Y.-I., and Basu, S. (2018).
 1023 Clinical Implications of Revised Pooled Cohort Equations for Estimating Atherosclerotic
 1024 Cardiovascular Disease Risk. Annals of Internal Medicine *169*, 20-29. 10.7326/M17-3011.
- 102585.van Buuren, S., and Groothuis-Oudshoorn, K. (2011). mice: Multivariate Imputation by Chained1026Equations in R. Journal of Statistical Software 45, 1 67. 10.18637/jss.v045.i03.
- 102786.Mbatchou, J., Barnard, L., Backman, J., Marcketta, A., Kosmicki, J.A., Ziyatdinov, A., Benner, C.,1028O'Dushlaine, C., Barber, M., Boutkov, B., et al. (2021). Computationally efficient whole-genome1029regression for quantitative and binary traits. Nat Genet 53, 1097-1103. 10.1038/s41588-021-00870-7.
- 103087.Bulik-Sullivan, B.K., Loh, P.-R., Finucane, H.K., Ripke, S., Yang, J., Patterson, N., Daly, M.J., Price,1031A.L., and Neale, B.M. (2015). LD Score regression distinguishes confounding from polygenicity in1032genome-wide association studies. Nature Genetics 47, 291-295. 10.1038/ng.3211.
- 103388.Brokamp, C., Wolfe, C., Lingren, T., Harley, J., and Ryan, P. (2018). Decentralized and reproducible
geocoding and characterization of community and environmental exposures for multisite studies. J1035Am Med Inform Assoc 25, 309-314. 10.1093/jamia/ocx128.

103689.Kulldorff, M. (1997). A spatial scan statistic. Communications in Statistics - Theory and Methods 26,10371481-1496. 10.1080/03610929708831995.



Figure 2



Figure 3



Figure 4



Figure 5



Figure S1



medRxiv preprint doi: https://doi.org/10.1101/2023.10.24.23297096; this version posted October 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Figure S2



Figure S3

а





Figure S4

Uncharacterized Symptoms eq Musculoskeleial Compleaner Complications Hematypoletic Genitourina_{ry} Congential Anonalies Dermatologic Endocrino Metabolic Neurological Circulatory System Infectious Diseases Neoplesins Respiratory Organs Organs Digestive Disorders Poisonings Mental Injuries Benign neoplasm of skin 40 -Inflammatory bowel disease 01 30 -190 20 -Neoplasm of uncertain behavior of skin Regional enteritis 10 PheCodes

Figure S5



UMAP1





Figure S8





Figure S10

